68 Hung y col.
Investigación Clínica 65(1): 2024
Cancer 2015; 6:206-213. https://doi.org/
10.1007/s12672-015-0232-3.
24. Bhattarai S, Klimov S, Mittal K, Krishna-
murti U, Li X, Oprea-Ilies G, Wetherilt C,
Riaz A, Aleskandarany M, Green A, Ellis I,
Cantuaria G, Gupta M, Manne U, Agboo-
la J, Baskovich B, Janssen EAM, Callagy
G, Walsh EM, Mehta A, Dogra A, Shet T,
Gajaria P, Traina T, Nggada H, Omonisi A,
Ahmed S, Rakha E, Rida P, Aneja R. Prog-
nostic role of androgen receptor in triple
negative breast cancer: a multi-institutio-
nal study. Cancers 2019; 11:995. https://
doi.org/10.3390/cancers11070995.
25. Melo M, Serrano S, Abaunza M. Androgen
receptor expression and prognosis in His-
panic/Latino women with triple negative
breast cancer. Rev Esp Patol 2022; 55:96-
104.
26. McGhan L, McCullough A, Protheroe C,
Dueck A, Lee J, Nunez R, Castle E, Gray
R, Wasif N, Goetz M, Hawse J, Henry T,
Barrett M, Cunliffe H, Pockaj B. Andro-
gen receptor-positive triple negative breast
cancer: a unique breast cancer subtype.
Ann Surg Oncol 2014; 21:361-367. https://
doi.org/10.1245/s10434-013-3260-7.
27. Astvatsaturyan K, Yue Y, Walts AE, Bose
S. Androgen receptor positive triple ne-
gative breast cancer: Clinicopathologic,
prognostic, and predictive features. PLoS
One 2018; 13:e0197827. https://doi.org/
10.1371/journal.pone.0197827.
28. Choi JE, Kang SH, Lee SJ, Bae YK. An-
drogen receptor expression predicts
decreased survival in early stage triple-
negative breast cancer. Ann Surg Oncol
2015; 22:82-89. https://doi.org/10.1245/
s10434-014-3984-z.
29. Jam S, Abdollahi A, Zand S, Khazaeipour
Z, Omranipour R, Najafi M. Androgen re-
ceptor expression in triple-negative breast
cancer. Arch Breast Cancer 2019; 6:92-95.
30. Sunar V, T Dogan H, Sarici F, Ates O, Akin
S, Baspinar B, Aksoy S, Altundag K. As-
sociation between androgen receptor sta-
tus and prognosis in triple negative breast
cancer. J BUON. 2018; 23:1325-1330.
31. Andre F, Arnedos M, Goubar A, Ghouad-
ni A, Delaloge S. Ki67--no evidence for its
use in node-positive breast cancer. Nat Rev
Clin Oncol 2015; 12:296-301. https://doi.
org/10.1038/nrclinonc.2015.46.
32. Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu
J, Di G, Liu G, Yu K, Shao Z, Wang Z. The
prognostic and predictive potential of Ki-
67 in triple-negative breast cancer. Sci Rep
2020; 10:225. https://doi.org/10.1038/
s41598-019-57094-3.
33. Zhao S, Ma D, Xiao Y, Li XM, Ma JL,
Zhang H, Xu XL, Lv H, Jiang WH, Yang
WT, Jiang YZ, Zhang QY, Shao ZM. Mo-
lecular subtyping of triple-negative breast
cancers by immunohistochemistry: Mole-
cular basis and clinical relevance. Onco-
logist 2020;25: e1481-e1491. https://doi.
org/10.1634/theoncologist.2019-0982.
34. Kim S, Moon BI, Lim W, Park S, Cho MS,
Sung SH. Feasibility of classification of tri-
ple negative breast cancer by immunohis-
tochemical surrogate markers. Clin Breast
Cancer 2018; 18:e1123-e1132. https://
doi.org/10.1016/j.clbc.2018.03.012.
35. Santonja A, Sánchez-Muñoz A, Lluch A,
Chica-Parrado MR, Albanell J, Chacón JI,
Antolín S, Jerez JM, de la Haba J, de Lu-
que V, Fernández-De Sousa CE, Vicioso L,
Plata Y, Ramírez-Tortosa CL, Álvarez M,
Llácer C, Zarcos-Pedrinaci I, Carrasco E,
Caballero R, Martín M, Alba E. Triple ne-
gative breast cancer subtypes and patholo-
gic complete response rate to neoadjuvant
chemotherapy. Oncotarget 2018; 9:26406-
26416. https://doi.org/10.18632/oncotar-
get.25413.
36. McNamara KM, Yoda T, Miki Y, Nakamu-
ra Y, Suzuki T, Nemoto N, Miyashita M,
Nishimura R, Arima N, Tamaki K, Ishida
T, Ohuchi N, Sasano H. Androgen recep-
tor and enzymes in lymph node metastasis
and cancer reoccurrence in triple-negative
breast cancer. Int J Biol Markers 2015;
30: e184-89. https://doi.org/10.5301/jbm.
5000132.
37. Abd-Elazeem MA, Abd-Elazeem MA.
Claudin 4 expression in triple-negative
breast cancer: Correlation with andro-
gen receptors and Ki-67 expression. Ann
Diagn Pathol 2015; 19:37-42. https://doi.
org/10.1016/j.anndiagpath.2014.10.003.